miR-34a, miR-708, miR-143, and miR-145 are negative regulators of CD44 in PCSCs and thus have the potential to serve as therapeutic drugs for advanced PCa patients (Ramesh et al., 2023). This evidence concerns the gene CD44 and posterior cortical atrophy.